Assessment of Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children Aged 0 to 4 Years and Their Household Members.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 08 2022
Historique:
entrez: 31 8 2022
pubmed: 1 9 2022
medline: 9 9 2022
Statut: epublish

Résumé

Few studies have prospectively assessed SARS-CoV-2 community infection in children aged 0 to 4 years. Information about SARS-CoV-2 incidence and clinical and virological features in young children could help guide prevention and mitigation strategies. To assess SARS-CoV-2 incidence, clinical and virological features, and symptoms in a prospective household cohort and to compare viral load by age group, symptoms, and SARS-CoV-2 lineage in young children, older children, and adults. This prospective cohort study enrolled 690 participants from 175 Maryland households with 1 or more children aged 0 to 4 years between November 24, 2020, and October 15, 2021. For 8 months after enrollment, participants completed weekly symptom questionnaires and submitted self-collected nasal swabs for SARS-CoV-2 qualitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) testing, quantitative RT-PCR testing, and viral lineage determination. For the analyses, SARS-CoV-2 Alpha and Delta lineages were considered variants of interest or concern. Sera collected at enrollment and at approximately 4 months and 8 months after enrollment were assayed for SARS-CoV-2 spike and nucleocapsid protein antibodies. Incidence, clinical and virological characteristics, and symptoms of SARS-CoV-2 infection by age group and correlations between (1) highest detected viral load and symptom frequency and (2) highest detected viral load and SARS-CoV-2 lineage. Among 690 participants (355 [51.4%] female and 335 [48.6%] male), 256 individuals (37.1%) were children aged 0 to 4 years, 100 (14.5%) were children aged 5 to 17 years, and 334 (48.4%) were adults aged 18 to 74 years. A total of 15 participants (2.2%) were Asian, 24 (3.5%) were Black, 603 (87.4%) were White, 43 (6.2%) were multiracial, and 5 (0.7%) were of other races; 33 participants (4.8%) were Hispanic, and 657 (95.2%) were non-Hispanic. Overall, 54 participants (7.8%) had SARS-CoV-2 infection during the surveillance period, including 22 of 256 children (8.6%) aged 0 to 4 years, 11 of 100 children (11.0%) aged 5 to 17 years, and 21 of 334 adults (6.3%). Incidence rates per 1000 person-weeks were 2.25 (95% CI, 1.28-3.65) infections among children aged 0 to 4 years, 3.48 (95% CI, 1.59-6.61) infections among children aged 5 to 17 years, and 1.08 (95% CI, 0.52-1.98) infections among adults. Children aged 0 to 17 years with SARS-CoV-2 infection were more frequently asymptomatic (11 of 30 individuals [36.7%]) compared with adults (3 of 21 individuals [14.3%]), with children aged 0 to 4 years most frequently asymptomatic (7 of 19 individuals [36.8%]). The highest detected viral load did not differ between asymptomatic vs symptomatic individuals overall (median [IQR], 2.8 [1.5-3.3] log10 copies/mL vs 2.8 [1.8-4.4] log10 copies/mL) or by age group (median [IQR] for ages 0-4 years, 2.7 [2.4-4.4] log10 copies/mL; ages 5-17 years: 2.4 [1.1-4.0] log10 copies/mL; ages 18-74 years: 2.9 [1.9-4.6] log10 copies/mL). The number of symptoms was significantly correlated with viral load among adults (R = 0.69; P < .001) but not children (ages 0-4 years: R = 0.02; P = .91; ages 5-17 years: R = 0.18; P = .58). The highest detected viral load was greater among those with Delta variant infections (median [IQR], 4.4 [3.9-5.1] log10 copies/mL) than those with infections from variants not of interest or concern (median [IQR], 1.9 [1.1-3.6] log10 copies/mL; P = .009) or those with Alpha variant infections (median [IQR], 2.6 [2.3-3.4] log10 copies/mL; P = .006). In this study, SARS-CoV-2 infections were frequently asymptomatic among children aged 0 to 4 years; the presence and number of symptoms did not correlate with viral load. These findings suggest that symptom screening may be insufficient to prevent outbreaks involving young children.

Identifiants

pubmed: 36044218
pii: 2795801
doi: 10.1001/jamanetworkopen.2022.27348
pmc: PMC9434363
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2227348

Investigateurs

Christine Council-DiBitetto (C)
Milena Gatto (M)
Maria Garcia-Quesada (M)
Tina Ghasri (T)
Amanda Gormley (A)
Kyley Guenther (K)
Kristi Herbert (K)
Maria Jordan (M)
Karen Loehr (K)
Jason Morsell (J)
Jennifer Oliva (J)
Jocelyn San Mateo (J)
Khadija Smith (K)
Kimberli Wanionek (K)
Cathleen Weadon (C)
Suzanne Woods (S)
Yan Li (Y)
Anna Kelleher (A)
Anna Uehara (A)
Ying Tao (Y)
Jing Zhang (J)
Brian Lynch (B)
Meghan Bentz (M)
Alex Burgin (A)
Mark Burroughs (M)
Morgan L Davis (ML)
Joseph C Madden (JC)
Sarah Nobles (S)
Jasmine Padilla (J)
Mili Sheth (M)
Dhwani Bhatra (D)
Jason Caravas (J)
Peter Cook (P)
Dakota Howard (D)
Kristine Lacek (K)
Clint Paden (C)
Ben Rambo-Martin (B)
Samuel Shepard (S)

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1249-1254
pubmed: 34499628
JAMA Intern Med. 2020 Nov 01;180(11):1447-1452
pubmed: 32780793
Emerg Infect Dis. 2020 Oct;26(10):2497-2499
pubmed: 32497001
Clin Infect Dis. 2022 Aug 24;75(1):e1128-e1136
pubmed: 34423834
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):271-278
pubmed: 35176003
JAMA Pediatr. 2021 Oct 1;175(10):e212025
pubmed: 34115094
J Infect. 2021 Oct;83(4):e1-e3
pubmed: 34419559
Clin Infect Dis. 2022 Aug 24;75(1):e715-e725
pubmed: 34922338
JAMA Pediatr. 2022 Mar 01;176(3):e216436
pubmed: 35044430
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Arch Dis Child. 2020 Dec 17;:
pubmed: 33334728
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33093026
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
Elife. 2021 Sep 27;10:
pubmed: 34569939
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734
pubmed: 34914670
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
JAMA Pediatr. 2022 Jan 1;176(1):59-67
pubmed: 34623377
Emerg Infect Dis. 2022 Feb;28(2):331-337
pubmed: 34876242
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Clin Infect Dis. 2021 Jun 1;72(11):e761-e767
pubmed: 32986120
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Pediatrics. 2022 Mar 1;149(3):
pubmed: 35194642
J Infect Dis. 2021 Mar 3;223(5):796-801
pubmed: 33064789
Euro Surveill. 2020 Dec;25(49):
pubmed: 33303065
N Engl J Med. 2021 Sep 2;385(10):954-956
pubmed: 34289272
Lancet Infect Dis. 2021 Feb;21(2):165
pubmed: 32445709

Auteurs

Ruth A Karron (RA)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Marissa K Hetrich (MK)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Yu Bin Na (YB)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Maria Deloria Knoll (MD)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Elizabeth Schappell (E)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Jennifer Meece (J)

Marshfield Clinic Research Institute, Marshfield, Wisconsin.

Erika Hanson (E)

Wisconsin State Laboratory of Hygiene, Madison.

Suxiang Tong (S)

COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia.

Justin S Lee (JS)

COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia.

Vic Veguilla (V)

COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia.

Fatimah S Dawood (FS)

COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH